The Buzz Surrounding Chemesis International Inc. (CSE: CSI) (OTC: CADMF)



Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, with operations in California and exploring expansion through Latin America.

Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution and retail. Chemesis has seed to sale operations, allowing for cost-effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods to provide consumers with quality cannabis products.

Investor Recap



The Process


Starting with our state of the art grow facility in Puerto Rico, which showcases a 2000+ grow light capacity and a 30,000+ lb overall grow capacity, Chemesis has multiple expansion opportunities currently under review in both Puerto Rico and California.


Chemesis is able to offer it’s clients all types of extractions, formulations & products, specializing in BHO Extraction, Alchohol Extraction, and CO2 Extraction and currently has the capacity to process over 2000lbs of raw material per day.


Chemesis is in sync with distributors around the world. With new regulations impacting the California market, we will emerge as a fully compliant first mover. In the Puerto Rico market, Chemesis has an established presence serving the entire island from seed to sale.


Chemesis is currently retailing exclusive products in Puerto Rico and actively engaging retail storefronts in the California market. In addition, Chemesis is working to open exclusively branded shops in multiple marketplaces.

Current Operations


Puerto Rico




Chemesis specializes in, and has invested in the equipment for, multiple extraction processes – BHO Extraction, Alcohol Extraction, CO2 Extraction, and others – and currently has the capacity to process over 2000lbs of raw material per day.   

Exclusive Brands


California Sap is one of the most rewarded companies in the cannabis industry today. Known for their experience, their purity, and their incredible products, Chemesis is excited to offer this exclusive brand.


Natural Ventures, our operations headquartered in Puerto Rico, holds strategic partnerships with an expanding number of leading brands in the cannabis industry spanning across multiple countries.


SAP Global is a state-of-the-art production facility located strategically in Cathedral City, California. The facility is able produce high quality legally compliant cannabis products for distribution in California.


Desert Zen Distribution & Transport, headquartered in the Coachella Valley, is all your California cannabis distribution needs under one roof.



Net Income Projections

Data provided by Chemesis International Inc.



Recent Developments

Chemesis International Inc. Announces Global Expansion Through Wholly Owned Subsidiary Chemesis Latin America

Chemesis International Inc. has opened its wholly owned subsidiary, Chemesis Latin America. Through this subsidiary, the company is exploring and completing advanced due diligence on opportunities for cultivation, production and export from the Latin American market. The company believes it will be able to quickly gain market share in Latin America through the use of its networks and existing expertise.

Chemesis’s long-term growth strategy is focused on international expansion. Globally, regulation changes are occurring for both medical and recreational cannabis, and as these changes occur, Chemesis intends to be a first mover by leveraging its existing networks and developing brands suited for the Latin American. Mexico is a great example of these changes, as president-elect Andres Manuel Lopez Obrador, who has the job of overseeing rule making and regulations around Mexico’s new marijuana law, unveiled a plan to change the country’s drug strategy in several big ways.

Colombia, another frontrunner in the Latin American cannabis market, is rapidly growing its capabilities. The government is hoping to grow up to 40.5 tons of cannabis per year, which would account for approximately 44 per cent of the licences issued globally. Colombia is estimated to capture as much as one-fifth of the global market, a value of $40-billion a year.

“Chemesis Latin America is a big step forward in our global growth strategy,” said chief executive officer, Edgar Montero. “We believe Chemesis has a major advantage in this region, as the recent acquisition of Natural Ventures can be leveraged to quickly capitalize on upcoming opportunities. With progressive regulations, Latin America becomes a key market that will be a major part of our portfolio. The company has positioned itself to take advantage of significant opportunities in both Mexico and Colombia. This allows Chemesis to execute on its ambitious growth strategy to identify opportunities that will build long-term shareholder value.”

The company plans to announce the specific countries and jurisdictions where it will be operating in the near future.

Chemesis International Inc. Signs Definitive Agreement To Acquire 80% Of Puerto Rico Based Natural Ventures Pr Llc

Chemesis International Inc. has entered into a definitive agreement to acquire 80 per cent of Natural Ventures PR LLC via its subsidiary Chemesis PR, a 100-per-cent-Puerto Rican company. The agreement amongst the parties has been submitted to the Puerto Rico Medical Cannabis Board for approval as per required by its regulatory framework. Natural Ventures is a seed to sale, medical cannabis company based in Caguas, Puerto Rico, a United States territory. Natural Ventures represents a significant opportunity that will catapult Chemesis into position as a leader in both medical and recreational cannabis cultivation and manufacturing.

Natural Ventures has been operational since early 2017 and currently is expanding to meet its growing patient demand. Natural Ventures is licensed to cultivate 100,000 square feet of cannabis and has 35,000 square ft of manufacturing floor space for high-quality cannabis products. It is currently producing solvent and carbon-dioxide-based extraction for its oil-based products, and it also is producing edibles and other cannabis products.

Puerto Rico legalized medical cannabis for qualifying health conditions in 2015 and permits the use of medical cannabis derivatives only (capsules, extractions, lotions, patches, edibles, flower and oils). Currently, there are 18 preapproved health conditions including HIV, cancer, multiple sclerosis, migraines, anxiety and epilepsy that are eligible to be treated with medical cannabis. Chemesis is poised to meet demand as the island continues to expand the number of qualifying conditions, and more patients receive permits.

“The acquisition of Natural Ventures is a very significant landmark for Chemesis,” said chief executive officer of Chemesis, Edgar Montero. “This acquisition gives the company access to a new consumer base as well as additional revenue opportunities. The operations in Puerto Rico unlock the ability to serve a large population for a variety of medical conditions, while being able to control costs and quality. The addition of Natural Ventures into the Chemesis family fits into our business model and growth strategy, as it will not only provide a strong benefit to our revenue stream but will unlock other opportunities in the global marketplace that are extremely important,” said Mr. Montero.

In exchange for an 80-per-cent interest in the capital stock of Natural Ventures PR LLC, the company will pay $2.25-million (U.S.) cash and $1,682,085 (U.S.) of stock valued at $1 (Canadian) per common share, subject to a 36-month phased lockup. Closing is subject to Puerto Rico Medical Cannabis Board approval which is anticipated within 30 days. The company has also agreed to make a convertible loan or capital contribution to Natural Ventures in the aggregate amount of $750,000 (U.S.) on an as-needed basis for expansion purposes.

Chemesis International Inc. Acquires 100% Of Desert Zen

Chemesis International Inc. has entered into and closed a definitive agreement to acquire 100 per cent of Desert Zen, a state-compliant, recreational and medicinal cannabis manufacturing, distribution and transportation company based in Cathedral City, Calif. This acquisition will allow Chemesis to increase its resources and significantly expand its foothold in the rapidly growing California market.

Desert Zen’s current facility is licensed under state and local laws to manufacture, package, distribute and transport quality cannabis products for recreational and medicinal uses. Desert Zen has a large existing network throughout the state of California that currently serves farmers and dispensaries, as well as other manufacturers, distributors and transporters. As a fully compliant cannabis manufacturer, distributor and transporter working with other fully compliant vendors, Desert Zen is able to track all products, monitor safety and ensure that all seed-to-sale laws are followed throughout the entire supply chain. Desert Zen’s catalogue of products includes a variety of cannabis products and will also include Chemesis’s flagship brand of California sap premium cannabis oils.

“State-wide compliance at each regulatory level in California requires substantial effort, and Chemesis is pleased to continue its growth as one of the few fully compliant first movers in the California market,” said Chemesis chief executive officer Edgar Montero. “Chemesis now has greater flexibility in its operations and can serve its customers more fully and efficiently. In addition, the acquisition of Desert Zen brings new product manufacturing, distribution and transportation opportunities to Chemesis’s considerable oil extraction capabilities.

“Desert Zen is an established cannabis manufacturer, distributor and transporter that continually is expanding its operations and will allow the company to further execute its growth strategy in the state of California,” said Mr. Montero. “The Desert Zen management team has a wealth of experience and an established network of growers, manufacturers and dispensaries. As Chemesis continues to grow, acquisitions such as this will ensure Chemesis is able to build consistent, long-term value for the company.”

Chemesis International is acquiring a 100-per-cent interest in Desert Zen in exchange for $500,000 (U.S.) of the company’s common stock at a deemed value of $1 (Canadian) per share, subject to a 36-month phased leakout restriction.

  1. Dan 1 week ago

    The U.S will legalize cannabis eventually.

  2. Ming 1 week ago

    That’s a nice landing page

  3. Devin 1 week ago

    The cannabis market is growing really fast. Some of the cannabis stocks hit all-time high.

  4. Warren 6 days ago

    A lot of cannabis stocks are trading at a very high valuation. People has high expectation about it.

    • Miguel 5 days ago

      TLRY is a 10 billion market cap company and is making no profit.

  5. Richard 4 days ago

    Consumers claim to prefer legal to illegal cannabis – and lower legal prices hit illegal sales more than lower illegal prices hit legal sales.

  6. Ryker 1 day ago

    There is news saying that Coca-Cola want to produce cannabis drinks. If it is true, it will be a big news.

Leave a Comment

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For chemesis international inc. financial news dissemination and PR services, has been compensated fifteen thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: